We are truely on our way, this signals a whole new trend of revenue growth and soon earnings. 
This news will assure that we will get new financing as we need it, and at decent rates.

All the Best

~~ dimar
.........................................

Response Biomedical Corporation Delivers Record Preliminary Revenues in First
Quarter - April 17, 2009 4:00PM ET

Revenues Grow 115% Over Q1 2008

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced preliminary
unaudited revenues for the three-month period ended March 31, 2009. First quarter
revenues increased 115% to approximately $2.526 million compared to $1.173 million
for the same period in 2008. This represents the highest revenues for any quarter in
the Company's history and, as expected, includes a significant contribution by the
Roche Diagnostics launch of our RAMP(R) Cardiac products in the U.S. Increased
revenues and reduced expenses are expected to result in a significantly lower loss
for the three-month period ended March 31, 2009 as compared to the same period in
2008. Complete first quarter 2009 unaudited interim financial results are expected
to be released on May 15, 2009.

"Our exceptional performance this quarter shows that our strategy is working," said
S. Wayne Kay, CEO, Response Biomedical. "Our blue-chip partners are placing orders
to support the launch of our infectious diseases and cardiovascular products into
the U.S. and we are developing new alliances, such as the one announced last month
with FIND, for additional uses of our technology platform. We are pleased that our
revenues in the first quarter of 2009 are in line with our expectations and we
anticipate continued strong year-over-year revenue growth as we move towards
profitability. We believe that these results will be of great assistance in our
efforts to address our current financing needs. Our success is due to the tireless
and outstanding work of our employees and the steadfast commitment of our partners."

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic
tests for use with its RAMP(R) Platform for clinical and environmental applications.
RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and
reliable information in minutes. It is ideally suited to both point of care testing
and laboratory use.

The RAMP(R) system consists of a Reader and single-use disposable test cartridges,
and has the potential to be adapted to more than 250 medical and non-medical tests
currently performed in laboratories. RAMP(R) clinical tests are commercially
available for the early detection of heart attack, congestive heart failure and
influenza through our commercial partners, Roche and 3M Health Care respectively.

In the non-clinical market, RAMP(R) Tests are currently provided for the
environmental detection of West Nile Virus, and Biodefense applications including
the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several
other product applications are under development.

Response has achieved CE Marking for its Reader and clinical tests and its Quality
Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R)
Influenza A/B Assay and RAMP 200 reader are not yet licensed for clinical use in
Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the
trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF".
For further information, please visit the Company's website at www.responsebio.com.

Statements contained in this press release relating to future results, events or
developments, for example, statements containing the words "believes," "may,"
"could", "plans," "will," "estimate," "continue," "anticipates," "intends,"
"expects", "goal" and similar expressions, are "forward-looking statements" or
"forward-looking information" under applicable United States and Canadian securities
laws. Forward-looking statements or information may involve, but are not limited to,
comments with respect to our planned activities, business plan and strategies and
their future implementation, and our expectations for our financial condition and
the results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us and
involve known and unknown risks, uncertainties and other factors that may cause
actual results, events or developments to be materially different from those
expressed or implied b
 y such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying
assumptions, and include, among other things, financial risks that would affect our
operations such as our limited available working capital and cash flows and whether
and for how long available funds will be sufficient to fund our operations and our
ability to raise additional capital as and when needed; our need for substantial
additional funding to conduct research and development and commercialization
activities; current financial market conditions which may negatively affect our
ability to obtain financing; our ability to meet the continued listing requirements
of the TSX under its ongoing delisting review; changing facility costs and other
risks relating to our facilities expansion plans; our ability to establish, and our
dependence upon, relationships with strategic alliance partners to develop and
commercialize products; technological changes that impact our existing products or
our abilit
 y to develop and commercialize our products; our ability to obtain and enforce
timely patent and other intellectual property protection for our technology and
products; our ability to obtain and maintain rights to technology from licensors;
liability for patent, product liability and other claims asserted against us;
commercialization limitations imposed by patents owned or controlled by third
parties; technical risk in research and development; adverse results or unexpected
delays in product development and clinical trials; our ability to retain, and our
reliance upon, third party suppliers, manufacturers, distributors and alliance
partners; our ability to attract and retain qualified personnel; our ability to
effectively and efficiently manage the planned growth of our operations; our
ability to obtain, and the timing of, necessary regulatory approvals; our ability
to profitably sell our products at prices that would be acceptable to third-party
reimbursement programs; com
 petition including competition from others with significantly more resources;
market acceptance of our products and the size of our markets; changes in business
strategy or development plans; changes in, or the failure to comply with,
governmental regulations; fluctuations in interest rates and foreign exchange
rates; seasonality including government budget cycles; general economic and
business conditions where we operate; and other factors referenced in our annual
report, our Annual Information Form (AIF) (Form 20-F in the U.S.) and other filings
with Canadian and United States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place
undue reliance on such forward-looking statements or information. We disclaim any
obligation to update, or to publicly announce any revisions to, any such statements
or information to reflect future results, events or developments, except as required
by law.

SOURCE: Response Biomedical Corp.

Bill Wickson, Director, Investor Relations, Response Biomedical Corporation, Tel
(604) 456-6073, Email: bwickson@responsebio.com